A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in patients with acute myeloid leukemia. Patients were randomly assigned to receive daunorubicin (45 mg/m(2) per day on days 1, 2,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Petersdorf, Stephen H., Kopecky, Kenneth J., Slovak, Marilyn, Willman, Cheryl, Nevill, Thomas, Brandwein, Joseph, Larson, Richard A., Erba, Harry P., Stiff, Patrick J., Stuart, Robert K., Walter, Roland B., Tallman, Martin S., Stenke, Leif, Appelbaum, Frederick R.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2013
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682338/
https://ncbi.nlm.nih.gov/pubmed/23591789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-466706
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker